...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance.
【24h】

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance.

机译:替加环素对耐红霉素的化脓性链球菌和无乳链球菌的体外活性:大环内酯和四环素的抗性机制。

获取原文
获取原文并翻译 | 示例

摘要

The activity of tigecycline was tested against erythromycin-resistant streptococci (107 Streptococcus pyogenes and 98 Streptococcus agalactiae strains). The presence of erythromycin and tetracycline resistance genes was determined by PCR. Among S. pyogenes strains the most prevalent gene was mef(A) (91.6%). The erm(B) gene was the most prevalent (65.3%) among S. agalactiae strains. Tigecycline proved to be very active against all the isolates tested (MIC at which 90% of the isolates tested were inhibited, 0.06 micro g/ml), including those resistant to tetracycline.
机译:测试了替加环素的抗红霉素链球菌活性(化脓性链球菌107株,无乳链球菌98株)。通过PCR确定红霉素和四环素抗性基因的存在。化脓链球菌菌株中最流行的基因是mef(A)(91.6%)。在无乳链球菌菌株中,erm(B)基因最为普遍(65.3%)。事实证明,替加环素对所有测试菌株(抑制90%测试菌株的MIC抑制,0.06微克/毫升)具有很高的活性,包括那些对四环素具有抗性的菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号